A Multi-Center, Randomized, Double-Blind, Placebo- (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy
Latest Information Update: 09 May 2025
At a glance
- Drugs MR-107A-02 (Primary) ; Tramadol
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors Mylan Specialty
Most Recent Events
- 08 May 2025 Primary endpoint (Summed Pain Intensity Difference (SPID) for MR-107A-02 versus placebo.) has been met, according to a Viatris media release.
- 08 May 2025 Results presented in a Viatris Media Release.
- 08 May 2025 According to a Viatris media release, Full results from both Phase 3 studies will be submitted for presentation at future congresses, including the upcoming PAINWeek 2025 conference in September.